Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$136.3m

Monopar Therapeutics Future Growth

Future criteria checks 3/6

Monopar Therapeutics is forecast to grow earnings and revenue by 45.9% and 76% per annum respectively while EPS is expected to grow by 61.9% per annum.

Key information

45.9%

Earnings growth rate

61.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate76.0%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

Earnings and Revenue Growth Forecasts

NasdaqCM:MNPR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268-9-5-43
12/31/2025N/A-13-12-113
12/31/2024N/A-7-8-73
9/30/2024N/A-6-6-6N/A
6/30/2024N/A-7-7-7N/A
3/31/2024N/A-8-7-7N/A
12/31/2023N/A-8-8-8N/A
9/30/2023N/A-9-8-8N/A
6/30/2023N/A-10-8-8N/A
3/31/2023N/A-10-7-7N/A
12/31/2022N/A-11-7-7N/A
9/30/2022N/A-10-8-8N/A
6/30/2022N/A-10-8-8N/A
3/31/2022N/A-10-8-8N/A
12/31/2021N/A-9-7-7N/A
9/30/2021N/A-9-7-7N/A
6/30/2021N/A-8-6-6N/A
3/31/2021N/A-7-5-5N/A
12/31/2020N/A-6-5-5N/A
9/30/2020N/A-5-4-4N/A
6/30/2020N/A-4-3-3N/A
3/31/2020N/A-4-3-3N/A
12/31/2019N/A-4-3-3N/A
9/30/2019N/A-4-3-3N/A
6/30/2019N/A-4-3-3N/A
3/31/2019N/A-4-3-3N/A
12/31/2018N/A-3-3-3N/A
9/30/2018N/A-3-3-3N/A
6/30/2018N/A-17N/A-4N/A
3/31/2018N/A-17N/A-3N/A
12/31/2017N/A-17N/A-3N/A
9/30/2017N/A-16N/A-2N/A
6/30/2017N/A-1N/A-1N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: MNPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MNPR is expected to become profitable in the next 3 years.

Revenue vs Market: MNPR is forecast to have no revenue next year.

High Growth Revenue: MNPR is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MNPR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:03
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Monopar Therapeutics Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.